Stay updated on Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial page
- Check4 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.7%
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page has removed a citation regarding health-related quality of life in advanced gastric cancer, which included an erratum reference.SummaryDifference0.2%
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check46 days agoChange DetectedThe page has been updated to include new identifiers related to the study on gastric adenocarcinoma, while significant details about the study's design and participant criteria have been removed.SummaryDifference13%
- Check54 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check61 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial page.